Anti-resorptive agents reduce the size of resorption cavities: A three-dimensional dynamic bone histomorphometry study

Bone

Volumn 57, Issue 1, 2013, Pages 277-283

  Matheny, J B ^a   Slyfield, C R ^a   Tkachenko, E V ^a   Lin, I ^a   Ehlert, K M ^a   Tomlinson, R E ^c   Wilson, D L ^c   Hernandez, C J ^a,b  

^a School of Operations Research and Industrial Engineering   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c Case Western Reserve University   (United States)

Author keywords

Bisphosphonates; Bone histomorphometry; Bone remodeling; Osteoporosis; Ovariectomy; SERMS

Indexed keywords

RALOXIFENE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; BONE STRUCTURE; CONTROLLED STUDY; FEMALE; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; RAT; SURFACE PROPERTY; THREE DIMENSIONAL IMAGING;

BISPHOSPHONATES; BONE HISTOMORPHOMETRY; BONE REMODELING; OSTEOPOROSIS; OVARIECTOMY; SERMS;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; ETIDRONIC ACID; FEMALE; OVARIECTOMY; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883737764     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.08.018     Document Type: Article

References (31)

1. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281-289.
2. Delmas P.D., Li Z., Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004, 19:330-337.
3. Parfitt A.M. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 2002, 17:1558-1559.
4. Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 2008, 42:1014-1020.
5. Parfitt A.M. Skeletal heterogeneity and the purposes of bone remodeling. Osteoporosis 2008, 71-92. Elsevier Academic Press, San Diego, CA, USA. 3rd ed. R. Marcus, D. Feldman, D.A. Nelson, C.J. Rosen (Eds.).
6. Allen M.R., Iwata K., Sato M., Burr D.B. Raloxifene enchances vertebral mechanical properties independent of bone density. Bone 2006, 39:1130-1135.
7. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
8. Cohen-Solal M.E., Shih M.S., Lundy M.W., Parfitt A.M. A new method for measuring cancellous bone erosion depth: application to the cellular mechanisms of bone loss in postmenopausal osteoporosis. J Bone Miner Res 1991, 6:1331-1338.
9. Storm T., Steiniche T., Thamsborg G., Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 1993, 8:199-208.
10. Monier-Faugere M.C., Friedler R.M., Bauss F., Malluche H.H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993, 8:1345-1355.
11. Wright C.D., Garrahan N.J., Stanton M., Gazet J.C., Mansell R.E., Compston J.E. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J Bone Miner Res 1994, 9:153-159.
12. Roux C., Ravaud P., Cohen-Solal M., de Vernejoul M.C., Guillemant S., Cherruau B., et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994, 15:41-49.
13. Boyce R.W., Paddock C.L., Gleason J.R., Sletsema W.K., Eriksen E.F. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 1995, 10:211-221.
14. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
15. Allen M.R., Erickson A.M., Wang X., Burr D.B., Martin R.B., Hazelwood S.J. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 2010, 86:67-71.
16. Recker R.R., Kimmel D.B., Dempster D., Weinstein R.S., Wronski T.J., Burr D.B. Issues in modern bone histomorphometry. Bone 2011, 49:955-964.
17. Hauge E.M., Mosekilde L., Melsen F. Stereological considerations concerning the measurement of individual osteoid seams and resorption cavities. Bone Miner 1994, 26:89-90.
18. Goff M.G., Slyfield C.R., Kummari S.R., Tkachenko E.V., Fischer S.E., Yi Y.H., et al. Three-dimensional characterization of resorption cavity size and location in human vertebral trabecular bone. Bone 2012, 51:28-37.
19. Slyfield C.R., Tkachenko E.V., Wilson D.L., Hernandez C.J. Three-dimensional dynamic bone histomorphometry. J Bone Miner Res 2012, 27:486-495.
20. Slyfield C.R., Niemeyer K.E., Tkachenko E.V., Tomlinson R.E., Steyer G.G., Patthanacharoenphon C.G., et al. Three-dimensional surface texture visualization of bone tissue through epifluorescence-based serial block face imaging. J Microsc 2009, 236:52-59.
21. Tkachenko E.V., Slyfield C.R., Tomlinson R.E., Daggett J.R., Wilson D.L., Hernandez C.J. Voxel size and measures of individual resorption cavities in three-dimensional images of cancellous bone. Bone 2009, 45:487-492.
22. Doube M., Klosowski M.M., Arganda-Carreras I., Cordelieres F.P., Dougherty R.P., Jackson J.S., et al. BoneJ: free and extensible bone image analysis in ImageJ. Bone 2010, 47:1076-1079.
23. Boyde A., Jones S.J. Pitfalls in pit measurement. Calcif Tissue Int 1991, 49:65-70.
24. Suzuki K., Takeyama S., Kikuchi T., Yamada S., Sodek J., Shinoda H. Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy. J Histochem Cytochem 2005, 53:1525-1537.
25. Soe K., Andersen T.L., Hobolt-Pedersen A.S., Bjerregaard B., Larsson L.I., Delaisse J.M. Involvement of human endogenous retroviral syncytin-1 in human osteoclast fusion. Bone 2011, 48:837-846.
26. Goldberg S.R., Georgiou J., Glogauer M., Grynpas M.D. A 3D scanning confocal imaging method measures pit volume and captures the role of Rac in osteoclast function. Bone 2012, 51:145-152.
27. Andersen T.L., Sondergaard T.E., Skorzynska K.E., Dagnaes-Hansen F., Plesner T.L., Hauge E.M., et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009, 174:239-247.
28. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
29. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002, 30:368-376.
30. Rogers A., Clowes J.A., Pereda C.A., Eastell R. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies. Bone 2007, 40:105-110.
31. Dempster D.W. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 2000, 15:20-23.